With over 30 years of experience in CMC development and commercialization, Dr. Waltermire will be responsible for all CMC across Venatorx’s portfolio including drug substance and drug product activities from preclinical development through clinical supplies for Phase 3 registration studies and eventual transition to commercial supply.
Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020.
With over 25 years of biopharmaceutical industry experience, including multiple product and line extension launches, Mr. Sargent will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.
Everest Medicines today announced top-line results from its Phase 1 clinical trial in China of taniborbactam (formerly VNRX-5133) in combination with cefepime for the treatment of infections caused by multi-drug resistant (MDR) pathogens. The study met its primary objective, demonstrating that the cefepime-taniborbactam combination treatment was safe and well tolerated among healthy Chinese volunteers with key pharmacokinetics parameters indicating no detectable signal of ethnic differences.
Venatorx Pharmaceuticals has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS) to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.
Venatorx Pharmaceuticals was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.
Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) today announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133). Cefepime-taniborbactam is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).
Everest Medicines announced the results from an in vitro study of taniborbactam (VNRX-5133) combined with cefepime. Findings from the study are published in the March 2020 issue of the Journal of Antimicrobial Chemotherapy. The paper is entitled “In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime, against MDR Gram-negative bacterial isolates from China”.